OncoMatch/Clinical Trials/NCT06463665
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Is NCT06463665 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for advanced non-squamous non-small-cell lung cancer.
Treatment: Olvimulogene nanivacirepvec · Platinum chemotherapy: carboplatin or cisplatin · Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC · Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab · Docetaxel — This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — front-line
Received at least 2 cycles and maximum of 6 cycles of front-line platinum-based chemotherapy with ICI-based therapy
Must have received: immune checkpoint inhibitor — front-line or maintenance
Reached first disease progression by radiological assessment while receiving front-line or maintenance ICI
Cannot have received: virus-based gene therapy
Have received prior virus-based gene therapy or therapy with cytolytic virus of any type
Lab requirements
Blood counts
adequate bone marrow function as well as adequate coagulation tests [International Normalized Ratio (INR)] and adequate immune function by lymphocyte count
Kidney function
adequate renal function
Liver function
adequate hepatic function
Have adequate renal, hepatic, bone marrow function as well as adequate coagulation tests [International Normalized Ratio (INR)] and adequate immune function by lymphocyte count
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Pioneer Research Center, LLC · Bullhead City, Arizona
- Clermont Oncology Center · Clermont, Florida
- Oncology & Hematology Associates of West Broward · Coral Springs, Florida
- Helios Clinical Research · Fort Lauderdale, Florida
- Bioresearch Partner · Hialeah, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify